Previous close | 6.22 |
Open | 6.22 |
Bid | 4.56 x 200 |
Ask | 6.14 x 100 |
Day's range | 6.07 - 6.36 |
52-week range | 2.70 - 9.97 |
Volume | |
Avg. volume | 89,198 |
Market cap | 258.495M |
Beta (5Y monthly) | 3.15 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.20 |
Earnings date | 02 Aug 2024 - 06 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 13.75 |
Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash equivalents and short-term investments of $310 million and extends cash runway into 2027 CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal g
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (“Foghorn”) (Nasdaq: FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share, before underwriting discounts and commissions, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 7,220,794 shares of its common stock at a price of $5.5099 per pre-funded warrant, which represents the per share
Last week, you might have seen that Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) released its quarterly result to the...